Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma-Reference-Cited by-同舟云学术

Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma

Published:2016-09-30 Issue:3 Volume:24 Page:770-777
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Kim In-Ho,Lee In Hee,Lee Ji Eun,Hong Sook Hee,Kim Tae-Jung,Lee Kyo-Young,Kim Young Kyoon,Kim Seung Joon,Sung Sook Whan,Park Jae Kil,Yoo Ie Ryung,Kim Yeon Sil,Kim Jung-Oh,Kang Jin Hyoung

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-016-5599-z.pdf

Reference39 articles.

1. Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer. 2006;52:207–12.

2. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin versus observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–97.

3. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant navelbine international trialist association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–27.

4. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:3552–9.

5. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006;59:790–800.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer;Cancers;2023-09-14

2. KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block;Therapeutic Advances in Respiratory Disease;2022-01

3. The Prognostic Role of MET Protein Expression Among Surgically Resected Non-small Cell Lung Cancer Patients: A Meta-Analysis;Frontiers in Oncology;2019-12-20

4. Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis;Molecular Diagnosis & Therapy;2019-07-25

5. c-MET as a biomarker in patients with surgically resected non-small cell lung cancer;Lung Cancer;2019-07